Literature DB >> 33834482

Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet?

Ana Blas-García1,2,3, Nadezda Apostolova4,1,2, Federico Lucantoni4,1, Andreu Martínez-Cerezuela4, Aleksandra Gruevska4,1, Ángela B Moragrega4,1, Víctor M Víctor1,2,3, Juan V Esplugues4,1,2.   

Abstract

Liver fibrosis (LF) occurs as a result of persistent liver injury and can be defined as a pathologic, chronic, wound-healing process in which functional parenchyma is progressively replaced by fibrotic tissue. As a phenomenon involved in the majority of chronic liver diseases, and therefore prevalent, it exerts a significant impact on public health. This impact becomes even more patent given the lack of a specific pharmacological therapy, with LF only being ameliorated or prevented through the use of agents that alleviate the underlying causes. Hepatic stellate cells (HSCs) are fundamental mediators of LF, which, activated in response to pro-fibrotic stimuli, transdifferentiate from a quiescent phenotype into myofibroblasts that deposit large amounts of fibrotic tissue and mediate pro-inflammatory effects. In recent years, much effort has been devoted to understanding the mechanisms through which HSCs are activated or inactivated. Using cell culture and/or different animal models, numerous studies have shown that autophagy is enhanced during the fibrogenic process and have provided specific evidence to pinpoint the fundamental role of autophagy in HSC activation. This effect involves - though may not be limited to - the autophagic degradation of lipid droplets. Several hepatoprotective agents have been shown to reverse the autophagic alteration present in LF, but clinical confirmation of these effects is pending. On the other hand, there is evidence that implicates autophagy in several anti-fibrotic mechanisms in HSCs that stimulate HSC cell cycle arrest and cell death or prevent the generation of pro-fibrotic mediators, including excess collagen accumulation. The objective of this review is to offer a comprehensive analysis of published evidence of the role of autophagy in HSC activation and to provide hints for possible therapeutic targets for the treatment and/or prevention of LF related to autophagy.
© 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Entities:  

Keywords:  LX-2; autophagy; fibrosis resolution; hepatic stellate cells; liver fibrosis; statins

Mesh:

Year:  2021        PMID: 33834482     DOI: 10.1002/path.5678

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  Macrophages evoke autophagy of hepatic stellate cells to promote liver fibrosis in NAFLD mice via the PGE2/EP4 pathway.

Authors:  Ying Cao; Weili Mai; Rui Li; Shuwei Deng; Lan Li; Yanxi Zhou; Qiushi Qin; Yue Zhang; Xingang Zhou; Ming Han; Pu Liang; Yonghong Yan; Yu Hao; Wen Xie; Jie Yan; Liuluan Zhu
Journal:  Cell Mol Life Sci       Date:  2022-05-19       Impact factor: 9.261

2.  Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less.

Authors:  Ana Blas-García; Nadezda Apostolova; Federico Lucantoni; Ana M Benedicto; Aleksandra Gruevska; Ángela B Moragrega; Isabel Fuster-Martínez; Juan V Esplugues
Journal:  Cell Death Dis       Date:  2022-04-20       Impact factor: 9.685

Review 3.  ER Disposal Pathways in Chronic Liver Disease: Protective, Pathogenic, and Potential Therapeutic Targets.

Authors:  Caroline C Duwaerts; Jessica L Maiers
Journal:  Front Mol Biosci       Date:  2022-01-31

Review 4.  Autophagy and Exosomes: Cross-Regulated Pathways Playing Major Roles in Hepatic Stellate Cells Activation and Liver Fibrosis.

Authors:  Eleftheria M Mastoridou; Anna C Goussia; Georgios K Glantzounis; Panagiotis Kanavaros; Antonia V Charchanti
Journal:  Front Physiol       Date:  2022-02-03       Impact factor: 4.566

5.  Uridine alleviates carbon tetrachloride-induced liver fibrosis by regulating the activity of liver-related cells.

Authors:  Wei V Zheng; Yaqin Li; Xianyi Cheng; Yanwei Xu; Tao Zhou; Dezhi Li; Yu Xiong; Shaobin Wang; Zaizhong Chen
Journal:  J Cell Mol Med       Date:  2021-12-30       Impact factor: 5.310

Review 6.  Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target.

Authors:  Chun-Liang Chen; Yu-Cheng Lin
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.